Teva submits BLA for fremanezumab to FDA for migraine prevention

Teva Pharmaceutical Industries has submitted a biologics licence application (BLA) for fremanezumab to the US Food and Drug Administration (FDA) for migraine prevention.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news